Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"

OA Location

https://pubmed.ncbi.nlm.nih.gov/31136226/

Author(s)

Mann, Johannes FE

Fonseca, Vivian

Mosenzon, Ofri

Raz, Itamar

Goldman, Bryan

more

Type

Journal Article

Date Issued

2019-05-28

Date Acceptance

2019-05-01

Citation

Circulation, 2019, 139 (22), pp.e1017-e1018

URI

http://hdl.handle.net/10044/1/90482

DOI

https://www.dx.doi.org/10.1161/CIRCULATIONAHA.119.040419

ISSN

0009-7322

Publisher

Lippincott, Williams & Wilkins

Start Page

e1017

End Page

e1018

Journal / Book Title

Circulation

Volume

139

Issue

22

Copyright Statement

© 2019 American Heart Association, Inc.

Identifier

https://www.ncbi.nlm.nih.gov/pubmed/31136226

Subjects

Cardiovascular Diseases

Diabetes Mellitus, Type 2

Humans

Hypoglycemic Agents

Liraglutide

Renal Insufficiency, Chronic

Humans

Cardiovascular Diseases

Diabetes Mellitus, Type 2

Hypoglycemic Agents

Renal Insufficiency, Chronic

Liraglutide

Cardiovascular System & Hematology

1102 Cardiorespiratory Medicine and Haematology

1103 Clinical Sciences

1117 Public Health and Health Services

Publication Status

Published

Coverage Spatial

United States